Prempro

Wyeth Pharmaceuticals, a division of Wyeth , believes these data are important because up to 20 percent of a woman's expected lifetime bone loss can occur in the years immediately following menopause.

Postmenopausal bone loss can lead to osteoporosis.

According to Robert Lindsay, MD, PhD, the lead author of this new report and Director, Clinical Research Center, Helen Hayes Hospital, these data add important new information about bone protection with low doses of PREMARIN or "While previous research has shown the overall change in BMD for the population studied, this study goes further by documenting the percentage of women taking low doses of PREMARIN or Lindsay.

"This information may be important when making treatment recommendations for women with menopausal symptoms who are also at risk of developing osteoporosis." The Women's HOPE Study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial of 2,673 healthy postmenopausal women (40 to 65 years of age).

The new report is based on a 2-year substudy of 822 Women's HOPE Study participants that evaluated the effects of various doses of PREMARIN (conjugated estrogens [CE]) and Read more...